XLO — Xilio Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1840233 ·
Last close
$9.04
Market Cap
$59.48M
52W High
$12.74
52W Low
$6.47
ADV30
10,877
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 18,692,000 | — | -3,491,000 | -6,373,000 | 154,254,000 | 136,040,000 | 81,990,000 |
| Mar 2026 | 12,648,000 | — | -14,112,000 | -9,529,000 | 163,487,000 | 150,333,000 | 90,943,000 |
| Dec 2025 | 13,686,000 | — | -11,836,000 | 10,360,000 | 154,685,000 | 137,531,000 | 119,412,000 |
| Sep 2025 | 19,066,000 | — | -1,929,000 | -16,287,000 | 133,694,000 | 103,764,000 | 141,789,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-56,313,000
Investing CF
$-1,052,000
Financing CF
$118,650,000
CapEx
$-1,074,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.55
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-428,318,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-42,243,000
Pretax Income TTM
$-31,300,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$64,092,000
EBITDA
$-30,030,000
Free Cash Flow
$-37,562,000
Enterprise Value
$-70,976,232
Total Cash
$136,040,000
Total Debt
$6,303,000
Shares Out
6,580,153
Trailing EPS
$-0.32
Book Value
$7.79
ROE
-55.0%
ROA
-13.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 43,766,000 | -41,982,000 | -35,036,000 | 154,685,000 | 119,412,000 | 35,273,000 | -4,992,000 |
| Dec 2024 | 6,344,000 | -59,645,000 | -58,241,000 | 71,075,000 | 53,477,000 | 17,598,000 | -18,378,000 |
| Dec 2023 | 0 | -79,133,000 | -76,404,000 | 60,926,000 | 24,099,000 | 36,827,000 | -68,620,000 |
| Dec 2022 | 0 | -89,149,000 | -88,222,000 | 139,165,000 | 33,518,000 | 105,647,000 | -75,723,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MREO | Mereo BioPharma Group plc | $59.09M | $0.37 | — |
| PRRUF | IMMUTEP Ltd | $58.95M | $0.04 | — |
| BOLD | Boundless Bio, Inc. | $60.51M | $2.66 | — |
| TLPH | TALPHERA, INC. | $61.25M | $1.18 | — |
| ZYBT | Zhengye Biotechnology Holding Ltd | $61.85M | $1.30 | — |
News headlines (Yahoo Finance, 1h cache)
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-02 20:30 · Yahoo
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
2026-08-12 11:30 · Yahoo
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
2026-06-29 11:30 · Yahoo
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
2026-05-12 11:30 · Yahoo
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
2026-05-12 12:40 · Yahoo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-07 20:30 · Yahoo
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
2026-04-16 11:30 · Yahoo
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?
2026-04-01 16:00 · Yahoo
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
2026-04-17 20:01 · Yahoo
3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership
2026-07-24 05:56 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.